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Abstract
Primary Amino Acid Derivatives (PAADs) (N′-benzyl 2-substituted 2-amino acetamides) are
structurally related to Functionalized Amino Acids (FAAs) (N′-benzyl 2- substituted 2-acetamido
acetamides) but differ by the absence of the terminal N-acetyl group. Both classes exhibit potent
anticonvulsant activities in the maximal electroshock seizure animal model and the reported
structure-activity relationships (SARs) of PAADs and FAAs differ in significant ways. Recently,
we documented that PAAD efficacy was associated with a hydrocarbon moiety at the C(2)-carbon,
while in the FAAs, a substituted heteroatom one atom removed from the C(2)-center was optimal.
Previously in this issue, we showed that PAAD activity was dependent upon the electronic
properties of the 4′-N′-benzylamide substituent, while FAA activity was insensitive to electronic
changes at this site. In this study, we prepared analogs of (R)-N′-benzyl 2-amino-3-
methylbutanamide to identify the structural components for maximal anticonvulsant activity. We
demonstrated that the SAR of PAADs and FAAs diverged at the terminal amide site and that
PAADs had considerably more structural latitude in the types of units that could be incorporated at
this position, suggesting that these compounds function according to different mechanism(s).
INTRODUCTION
Epilepsy is a heterogeneous mixture of disorders characterized by neuronal hyperexcitability
and hypersynchronous neuronal firing, and it affects up to 1% of the world’s population.1
There are over 40 antiepileptic drugs (AEDs) currently in clinical use,2 yet, some 30% of
patients are pharmacoresistant and do not respond to at least two of the first-line AEDs.3
Furthermore, compliance is often limited by adverse side effects (e.g., drowsiness, dizziness,
nausea), experienced by nearly 40% of patients.4 Novel compounds with increased efficacy
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and decreased toxicity are needed to improve the quality of life of those suffering from
epilepsy.
We recently reported that Primary Amino Acid Derivatives (PAADsa, 1) exhibit potent
anticonvulsant activities in the maximal electroshock seizure (MES) test5 in rodents,6 with
activities approaching that of many clinical AEDs.7 Significantly, the structure-activity
relationship (SAR) for PAADs and their N-acetylated analogs, the Functionalized Amino
Acids (FAAs, 2), differed in several ways. First, PAAD anticonvulsant activity, unlike the
FAAs, did not improve when a substituted heteroatom was included one atom removed from
the C(2) chiral center.6 Second, PAAD activity was sensitive to the electronic properties of
para-substituents on the N′-benzylamide ring, where activity was retained with an electron-
withdrawing group but lost upon inclusion of an electron-releasing group.8 By comparison,
FAAs containing either electron-donating or electron-withdrawing groups at the para-
position provided compounds with excellent anticonvulsant activities.9 Third, the maximal
activity for C(2)-hydrocarbon PAADs resided in the D-configuration, similar to the FAAs,
but the differences in the ratio of the active stereoisomer to the less-active stereoisomer
(eudismic ratio)10 differed widely. For (R)-3 and (S)- 3, the eudismic ratio in mice exceeded
20, while for (R)-4 and (S)-4 it was 3. For FAAs, the eudismic ratio was consistently above
10.9, 11, 12 The stark contrast between PAAD and FAA activity was most apparent for C(2)-
hydrocarbon derivatives, where the C(2)-hydrocarbon was a branched alkyl moiety. We
found that the C(2)-isopropyl PAAD (R)-3 (MES ED50 = 15 mg/kg) and C(2)-tert-butyl
PAAD (R)-4 (MES ED50 = 14 mg/kg) were potent anticonvulsants, while their FAA
counterparts (R)-5 (MES ED50 = >100, <300 mg/kg) and (R)-6 (MES ED50 = > 300 mg/kg)
were not.6 Collectively, these results suggest that the C(2)-hydrocarbon PAADs represent a
novel class of anticonvulsants.
aAbbreviations: AED, antiepileptic drug; ASP, Anticonvulsant Screening Program; CMDT, 2-chloro-4,6-dimethoxy-1,3,5-triazine;
CNS, central nervous system; DMAP, 4- dimethylaminopyridine; DMTMM, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-
methylmorpholinium chloride; ED50, effective dose (50%); FAA, functionalized amino acid; FAK, functionalized amido ketone; ip,
intraperitoneally; MAC, mixed anhydride coupling; MES, maximal electroshock seizure; NINDS, National Institute of Neurological
Disorders and Stroke; PAAD, primary amino acid derivative; PI, protective index; po, orally; SAAD, secondary amino acid
derivative; SAR, structure-activity relationship; scMet, subcutaneous Metrazol®; TD50, neurological impairment (toxicity, 50%);
TAAD, tertiary amino acid derivative; TFA, trifluoroacetic acid.
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The differences in the PAAD and FAA SAR have led us to question the optimal chemical
framework for PAADs. At the outset,6 we assumed that PAADs and FAAs would require
similar structural features for maximal activity. Among these were the diamine backbone
containing a carbonyl unit and a N′-terminal benzylamide. In the present study, we
systematically modified six sites in the core structure of PAAD 3. Significantly, we found
that several key structural motifs associated with maximal FAA seizure protection were not
necessary for potent PAAD activity. These findings provided additional evidence that C(2)-
hydrocarbon PAADs are a distinct, new class of potent anticonvulsants. The structural
simplicity of these PAADs, and the excellent water solubility of their corresponding salts,
provide opportunities for further development.
RESULTS AND DISCUSSION
Choice of Compounds
C(2)-Hydrocarbon PAADs possess significant anticonvulsant activities and our studies
indicated that many of the FAA structural hallmarks do not apply to PAADs.6, 8 Therefore,
we investigated the originally proposed PAAD structural framework. For most of our
studies, we systematically modified (R)-C(2)-isopropyl PAAD 3, which was among the most
potent PAADs discovered. Six structural features common to both PAADs and FAAs were
examined by preparing 7–24 (Figure 1): the carbonyl unit (Site A); the amide bond (Site B);
the amide methylene linker length (Site C); the regiosubstitution of the N′-benzylamide (Site
D); the need for a N′-benzylamide (Site E); and the C(2)-amino functionality (Site F). All
C(2)- isopropyl PAAD analogs (7–18, 23, 24) were synthesized in the (R)-configuration. For
N′-benzyl 2-aminobutanamide 19 and N-benzyl 2-hydroxybutanamide 22, we synthesized
the (R)- configuration, for 21, we prepared the (R,S) and (S)-configurations, and N-benzyl
butanamide (20) does not have a chiral center.
C(2)-Isopropyl PAAD analogs (Sites A–C)
The importance of the carbonyl unit for FAA anticonvulsant activity has been demonstrated
by an isoelectronic substitution of the amide carbonyl with a thiocarbonyl group,12 and we
conducted a similar investigation using (R)-7 (Site A). We further examined the value of the
carbonyl unit by replacing it with a methylene group ((R)-8).
We have reported that functionalized amido ketones (FAKs) exhibit significant
anticonvulsant activities that were comparable to FAAs; however, an increase in
neurological toxicity was also observed (Site B).13 In a similar manner, we replaced the
nitrogen of the amide bond in (R)-3 with a methylene group ((R)-9) or oxygen ((R)-10) to
create either a primary amino ketone or primary amino ester, respectively.
The distance between the amide bond and the aromatic ring was briefly investigated for
FAAs, and maximal activity was seen for the N′-benzylamide moiety (n = 1). Therefore, we
examined the anticonvulsant activities of PAADs that contain 0–4 methylene units between
the amide bond and the aromatic ring ((R)-3, (R)-11–14) (Site C).
Regiosubstitution in N′-Benzylamide PAADs (Site D)
Recently, we systematically evaluated the effect of a fluoro and trifluoromethoxy group at
the 2′, 3′, and 4′ postions in the N′-benzyl moiety of FAAs and determined that the 4′
derivatives displayed the highest level of anticonvulsant activity,9 consistent with previous
studies.11, 14 Accordingly, we evaluated the effect of a trifluoromethoxy group at the 2′, 3′,
and 4′ positions of PAAD (R)-3 by preparing (R)-15, (R)-16, and (R)-17,8 respectively.
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N′-Substituted C(2)-isopropyl PAADs (Site E)
We evaluated several N′-substituted FAAs, including a N′-methylamide, N′-
benzhydrylamide, and N′-benzylamide, and found that the N′-benzylamide unit is necessary
for the excellent anticonvulsant activity of FAAs.15 We substituted the aromatic ring in
(R)-3 for a cyclohexyl ring ((R)-18) to examine the influence of the planar ring system on
anticonvulsant activity.
α-Substituted N-benzylbutanamides (Site F) and N-Substituted C(2)-Isopropyl PAADs (Site
F′)
In our final analysis we examined the importance of the amino group and amine substitution.
The limited availability of 2-substituted 3-methylbutanoic acid reagents prompted the
investigation of N-benzylbutanamide derivatives ((R)-19, 20, (R,S)-21, (S)-21, and (R)-22)
instead of N′-benzyl 3-methylbutanamide derivatives (Site F). Previously, the C(2)-
acetamido of (R,S)-N′-benzyl 2-acetamido-2-phenylacetamide ((R,S)-25, ED50 = 20 mg/kg)
was systematically replaced with a hydrogen, methyl, hydroxy, methoxy, or halogen group.
The hydroxy and methoxy groups provided moderate MES activities (ED50 = >30, <100
mg/kg) but were appreciably less active than the parent FAA.16 In a similar study, the C(2)-
acetamido group of (R,S)-N′-benzyl 2-acetamido-3-methoxypropionamide ((R,S)-26, ED50 =
8.3 mg/kg) was replaced with a methyl, hydroxy, and amino group. The methyl and amino
groups also resulted in moderate MES activities (ED50 = >30, <100 mg/kg) but, again, the
activities were lower than the corresponding FAA.17 Accordingly, both studies concluded
that the C(2)-acetamido group showed superior anticonvulsant activity. We conducted a
similar investigation in which we replaced the amino group in (R)-19 with a hydrogen (20),
methyl ((R,S)-21), or hydroxy group ((R)-22). The moderate activity of (R,S)-21 prompted
our efforts to prepare (R)-21 and (S)-21 to determine if anticonvulsant activity resided in the
(R)-stereoisomer. We successfully synthesized (S)-21 but were unable to prepare (R)-21.
Finally, to assess the importance of N-terminal substitution (Site F′), we prepared the
Secondary Amino Acid Derivative (SAAD) (R)-23 and the Tertiary Amino Acid Derivative
(TAAD) (R)-24 in the C(2)-isopropyl series. Earlier studies did not reveal a general pattern
to correlate anticonvulsant activity with amine substitution.18–20 We observed that N-amine
substitution improved anticonvulsant activity in several cases, but in other compounds, we
saw a loss of activity.
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Thioamide (R)-7 was prepared by treating (R)-276 with excess Lawesson’s reagent at
reflux,12 followed by trifluoroacetic acid (TFA) deprotection of the t-Boc group (Scheme 1).
We were mindful of the potential for thiation of the carbamate carbonyl in (R)-27, but
the 13C NMR spectrum contained a signal at ~155 ppm, the typical shift for a carbamate
carbon, rather than ~190 ppm for the thiocarbamate.21 In agreement with the proposed
structure of (R)-27, we observed the thioamide carbon signal in the 13C NMR at 205 ppm.
Diamine (R)-814 was synthesized by directly reducing (R)-36 with borane in THF (Scheme
2). We followed a previously reported procedure14 but changed the workup.
We synthesized PAAD (R)-9 by coupling (R)-296 with N,O-dimethylhydroxylamine
hydrochloride (HCl) in the presence of 2-chloro-4,6-dimethoxy-1,3,5-triazine (CMDT) and
base22 to give Weinreb amide (R)-30 (Scheme 3). Weinreb amides readily react with
Grignard reagents and are widely known as useful precursors to ketones.22–24 Accordingly,
(R)-30 was reacted with phenethylmagnesium bromide to give (R)-31, followed by HCl
deprotection to give PAAD (R)-9 as a HCl salt.
We synthesized (R)-32 from (R)-296 using a mild esterification method 25 that employed
benzylchloroformate in the presence of base and catalytic amounts of 4-
dimethylaminopyridine (DMAP) (Scheme 4). Subsequent TFA deprotection of (R)-32 gave
PAAD (R)-10.
The C(2)-isopropyl PAAD analogs (R)-11–16 and (R)-18 were synthesized by coupling
(R)-296 with commercially available amines (33–39) and using the standard mixed
anhydride coupling (MAC) procedure,26 to give amides (R)-40–46, followed by TFA
deprotection to the corresponding PAADs (Scheme 5).
PAADs 20, (R,S)-21, (S)-21, and (R)-22 were synthesized from commercially available
carboxylic acids 47, (R,S)-48, (S)-48, and (R)-49 (Scheme 6). For (R)-20, (R,S)-21, and
(S)-21, we used the MAC procedure with benzylamine. We attempted to prepare (R)-21 to
compare its pharmacological activity with (S)-21 but were unsuccessful.27 PAAD (R)-22
was prepared by treating (R)-49 with benzylamine in the presence of the commercially
available catalyst, 3,5- bis(trifluoromethyl)benzeneboronic acid28 (50) (Scheme 6).
SAAD (R)-23 was prepared in three steps, beginning with the t-Boc protection of
commercially available acid (R)-51 to give (R)-52 (Scheme 7). (R)-52 was coupled with
benzylamine using the MAC procedure to give amide (R)-53 and then HCl deprotected to
give SAAD (R)-23 as the HCl salt.
Synthesis of TAAD (R)-24 began with reductive condensation of D-valine ((R)-54) with
formaldehyde using 10% Pd-C in the presence of H2 to give (R)-55 (Scheme 8).29–31 (R)-55
was coupled with benzylamine using the condensing reagent 4-(4,6-dimethoxy-1,3,5-
triazin-2-yl)-4- methylmorpholinium chloride (DMTMM)32 to give TAAD (R)-24.
In the experimental section, we detail the final step (synthetic procedure and
characterization) for all compounds evaluated in the animal models. In the Supporting
Information, we provide our experimental procedures for all compounds prepared and their
physical and spectroscopic properties.
Pharmacological Activity
PAADs 7–22 and 24 were evaluated for anticonvulsant activity using the MES test at the
National Institute of Neurological Disorders and Stroke Anticonvulsant Screening Program
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(NINDS ASP), following the procedures described by Stables and Kupferberg,5 and
described in the preceeding paper.8 PAAD 23 was evaluated for anticonvulsant activity at
UCB Pharma, following the procedures described by Klitgaard,33 as previously reported.8
The pharmacological data from the MES tests are summarized in Tables 1 and 2. PAADs
tested at the NINDS ASP were evaluated in the subcutaneous Metrazol® (scMet) seizure
model5 and displayed little to no protection.27
Compound (R)-3 emerged as a potent anticonvulsant (MES ED50 = 15 mg/kg) that
possessed pain attenuating properties (formalin ED50 = 15 mg/kg) from the SAR
investigation at the C(2)-carbon.6 This excellent activity came as a surprise since it did not
follow the trends observed in the FAA series. Therefore, we have questioned several aspects
of the original PAAD structural framework to determine if the basic tenets of the FAA
blueprint applied to this C(2)- hydrocarbon PAAD. We investigated the importance of six
properties (Sites A–F) that were common in the FAAs and report their anticonvulsant
activity and neurological toxicity in Tables 1 and 2.
First, we determined the effect of the carbonyl unit (Site A) on anticonvulsant activity
(Table 1). Replacement of the carbonyl unit in (R)-3 with a thiocarbonyl unit to give (R)-7
resulted in decreased MES activity in mice (ED50 (mg/kg): (R)-3, 15; (R)-7, >30, <100), but
notable activity was observed in rats (ED50 = <30 mg/kg). Reducing the carbonyl unit in
(R)-3 to a methylene group to provide (R)-8 led to decreased activity in both mice (ED50 =
>30, <100 mg/kg) and rats (ED50 = >30 mg/kg).
Next, we determined the effect of the amide bond (Site B) on anticonvulsant activity (Table
1). Converting the amide (R)-3 (Y = NH) to ketone (R)-9 (Y = CH2) decreased the MES
activity (ED50 (mg/kg): (R)-3, 15; (R)-9, >30, <100) and conversion to the ester (R)-10 (Y =
O) abolished activity (ED50 = >300 mg/kg).
Then, at Site C we looked at the optimal methylene linker length between the amide bond
and the aromatic ring (Table 1). Direct linkage of the aromatic ring to the amide bond to
give (R)-11 (n = 0) resulted in a significant drop in activity from the parent compound (R)-3
(n = 1) (ED50 (mg/kg): (R)-3, 15; (R)-11, >30, <100). However, extending the linkage of the
parent compound (R)-3 (n = 1) by one methylene unit to provide (R)-12 (n = 2) increased
anticonvulsant activity by ~30% (ED50 = 10 mg/kg). The activity increase was associated
with a neurotoxicity increase over the parent compound (TD50 (mg/kg): (R)-3, 70; (R)-12,
50); however, the PI of (R)-3 (4.8) and (R)-12 (5.0) were nearly equal. Extending the linker
by another carbon to give (R)-13 (n = 3) led to comparable activity with (R)-3 (ED50 (mg/
kg): (R)-3, 15; (R)-13, 16), but the increased toxicity for (R)-13 (TD50 = 43 mg/kg) reduced
the PI to 2.7. A final extension to n = 4 to give (R)-14 resulted in comparable activity in
mice (ip) with (R)-3 and (R)- 13 (ED50 (mg/kg): (R)-14, 11; (R)-3, 15; (R)-13, 16), with a PI
of 3.5. The anticonvulsant activities of (R)-12–14 were surprising since in the FAA series,
an increase in the methylene linkage led to a sharp drop in activity.34
Site D compared the effect of substitution on the N′-benzylamide ring, where we
systematically placed a trifluoromethoxy group at the 2′ ((R)-15), 3′ ((R)-16), and 4′-
positions ((R)-17) (Table 1). All regiosubstitutions displayed excellent MES activities in
mice (ED50 (mg/kg): (R)-15, 9.2; (R)-16, 7.1; (R)-17, 16). The ED50 value for (R)-16 was 2-
fold more active than the parent compound (R)-3 (ED50 = 15 mg/kg) but the increase in
activity was associated with an increase in neurotoxicity (ED50 (mg/kg): (R)-3, 70; (R)-16,
30). Comparison of the MES activity in rats (Table 1) showed ~3-fold drop in activity going
from (R)-3 to (R)-15 (ED50 (mg/kg): (R)-3, 11; (R)-15, 33). The MES activity of (R)-16 in
the rat (ED50 = 10 mg/kg) was comparable with (R)-3 (ED50 = 11 mg/kg) but there was a
sharp increase in behavioral toxicity (TD50 (mg/kg): (R)-3, >500; (R)-16, 43). The potent
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anticonvulsant activity observed for (R)-15 led us to evaluate this compound in the formalin
neuropathic pain model35 where we observed excellent activity in the inflammatory phase
(ED50 = 9.2 mg/kg, data not shown).36
Next, we examined the need for a benzyl moiety (Site E) (Table 1). We replaced the
aromatic ring ((R)-3) with a cyclohexyl ring ((R)-18) and observed a decrease in
anticonvulsant activity (ED50 (mg/kg): (R)-3, 15; (R)-18, >30, <100). When (R)-18 was
evaluated in the rat, we found this PAAD to have excellent activity (ED50 = ~15 mg/kg).
While our data indicates that the N′-benzyl substituent is preferred over the saturated N′-
cyclohexylmethyl unit, we did not anticipate the anticonvulsant activity of (R)-18.
Finally, we investigated the importance of the C(2)-amino functionality (Site F) by
comparing the unsubstituted N-benzyl butanamide 20 (X = H), the methyl-substituted N-
benzyl butanamide (R,S)-21 and (S)-21 (X = CH3), and the hydroxy-substituted N-benzyl
butanamide (R)-22 (X = OH) with the parent PAAD (R)-19 (X = NH2) (Table 2).
Compounds 20 and (R)-22 gave similar, modest activity (ED50 = >30, <100 mg/kg) in mice
and no appreciable activity in rats (ED50 = >30 mg/kg). (R,S)-21 also displayed modest
protection in mice (ED50 = 56 mg/kg) with minimal neurotoxicity (TD50 = 165 mg/kg), and
moderate activity in rats (ED50 = 51 mg/kg) without any detectable behavioral toxicity
(TD50 = >500 mg/kg). We were surprised by the activity of (R,S)-21 since the methyl group
lacks the hydrogen bonding capabilities afforded by an amino or a hydroxy group.
Evaluation of (S)-21 showed a decrease in anticonvulsant activity (ED50 = >100, <300 mg/
kg), suggesting that activity resided predominantly in the (R)-isomer. Unfortunately, we
were unable to complete the synthesis of (R)-21 to confirm this suggestion. The activities of
the primary (PAAD), secondary (SAAD), and tertiary (TAAD) amino acid analogs of (R)-N
′-benzyl 2-amino-3-methylbutanamide ((R)-3) are summarized in Table 2 (Site F′).
Comparison of the SAAD (R)-23 with the PAAD (R)-3 showed decreased activity in the
MES test (ED50 (mg/kg): (R)-3, 15; (R)-23, 25). Furthermore, comparison of the TAAD
(R)-24 with the SAAD (R)-23 showed an additional decrease in activity in the MES test
(ED50 (mg/kg): (R)-23, 25; (R)-24, >30, <100). Therefore, the MES data for PAAD (R)-3,
SAAD (R)-23, and TAAD (R)-24 revealed a linear decrease in anticonvulsant activity as we
successively incorporated methyl groups at the C(2)-amine site. This trend differed from the
reported pattern for racemic C(2)-methyl and C(2)-CH2OCH3 PAADs, in which successive
N-methylation led to non-linear trends in MES activity.18
Our findings indicated that PAAD anticonvulsant activity increased when a N-
phenethylamide moiety (Table 1, (R)-12) was used and when an electron-withdrawing
substituent (OCF3) was incorporated on the aromatic ring (Table 1, (R)-15–17).
Accordingly, we prepared three mono-fluoro regioisomers of (R)-N-phenethyl 2-amino-3-
methylbutanamide, ((R)- 56–58) using the same general procedure outlined in Scheme 5.
We observed that anticonvulsant activity remained high in the MES test (mice, ip) for all
three regioisomers (ED50 (mg/kg): (R)- 56, 27; (R)-57, 20; (R)-58, >10, <30), but there was
no apparent benefit over the parent, unsubstituted PAAD (R)-12 (MES ED50 = 10 mg/kg).
However, we observed an increase in activity and a decrease in toxicity in the MES test for
(R)-56 going from mice (ip) to rats (po). (R)-58 exhibited only slightly better activity than
the corresponding benzyl analog (R)-598 (ED50 = 32 mg/kg), in terms of potency in the
MES test and PI values (Table 1).
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Examination of PAAD Sites A–F revealed that the amide bond (Sites A and B) was
important for effective seizure protection and altering this unit affected the hydrogen
bonding properties of the compounds. Assessment of the methylene linker (Site C) showed
that at least one carbon between the amide bond and the aromatic rings was necessary for
anticonvulsant activity but incorporation of up to three additional methylene units provided
excellent activity. When considering activity, toxicity, and the protective index for these
C(2)-isopropyl PAADs, the optimal linker length appeared to be when n = 2, instead the n =
1, as seen in the FAAs. Similarly, we found that replacement of the benzylamide group by a
cyclohexylmethylamide (Site E) led to lower anticonvulsant activity, but the drop was
modest. Thus, there seems to be structural latitude at Sites C and E, where modifications
retain excellent activities. Comparison of trifluoromethoxy regioisomers of (R)-N′-benzyl 2-
amino-3-methylbutanamide (Site D) revealed that superb seizure protection was associated
with all positions. The activity increase was associated with a neurotoxicity increase but the
PI values were comparable with the parent, unsubstituted PAAD (R)-3. Lastly, we evaluated
our choice of the C(2)-amino group (Site F) since the earlier SAR studies were centered
around primary amino acid derivatives.6, 8 Of the C(2)-groups investigated, the amino group
was most active but was not mandatory for activity. The activities of the primary (PAAD),
secondary (SAAD), and tertiary (TAAD) amino acid analogs of (R)-N′-benzyl 2-amino-3-
methylbutanamide ((R)-3) showed a steady loss of anticonvulsant activity with N-
methylation. Collectively, the findings of this study, along with the earlier observations that
the anticonvulsant activity of C(2)-hydrocarbon PAADs do not improve when a substituted
heteroatom is included one atom removed from the C(2)-center6 and that PAAD activity is
sensitive to the electronic effects of N′-benzylamide substituents,8 indicated that the C(2)-
hydrocarbon PAADs have an unique SAR and. Future work will investigate PAAD
mechanism of action to determine if the difference in observed efficacy of PAADs and




The general methods used in this study were identical to those previously reported6 and are
summarized in the Supporting Information. All compounds were checked by TLC, 1H
and 13C NMR, MS, and elemental analyses. The analytical results were within ±0.40% of
the theoretical value. The TLC, NMR, and the analytical data confirmed the purity of the
products was ≥95%.
General Procedure for PAAD Preparation Using TFA Deprotection (Method A)
TFA (15 equiv) was added to an anhydrous CH2Cl2 solution of the tBoc-protected N′-
benzylamide PAAD (0.3 M) at room temperature. The solution was stirred (1 h) and then the
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solvent was evaporated in vacuo. The crude product was subjected to acidic workup or basic
workup. Acidic: The crude product was diluted with CH2Cl2 and extracted with aqueous 1
M HCl (3x). The combined aqueous layers were washed with CH2Cl2 (2x), basified (pH 10–
12) with aqueous 4 M NaOH, and extracted with CH2Cl2 (3x). The combined organic layers
were washed with brine (2x), dried (Na2SO4), evaporated in vacuo, and purified by column
chromatography (SiO2). Basic: The crude product was diluted with CH2Cl2 and washed
with aqueous 1 M Na2CO3 (3x). The aqueous layers were combined and washed with
CH2Cl2 (2x). All of the CH2Cl2 layers were combined and successively washed with H2O
(2x) and brine (2x), dried (Na2SO4), evaporated in vacuo, and purified by column
chromatography (SiO2).
General Procedure for the Preparation of N′-Benzylamide Amino Acid Derivatives Using
the Mixed Anhydride Coupling (MAC) Method (Method B)
An anhydrous THF solution of carboxylic acid (0.5–2.0 M) was cooled to −78 °C in a dry
ice/acetone bath under an inert atmosphere (Ar or N2), and 4-methylmorpholine (NMM)
(1.3–1.5 equiv) was added. After the mixture was stirred (2–10 min), isobutyl chloroformate
(IBCF) (1.1–1.5 equiv) was added leading to the precipitation of a white solid. The reaction
was allowed to proceed for an additional 15–25 min, and then benzylamine (1.05–1.36
equiv) was added at −78 °C. The reaction mixture was allowed to stir at room temperature
(1.5 h), and then the insoluble salts were filtered. The organic layer was concentrated in
vacuo, and the product was purified by column chromatography (SiO2).
(R)-N′-Benzyl 2-Amino-3-methylbutanethioamide ((R)-7)
Utilizing Method A with (R)-28 (1.72 g, 5.34 mmol), TFA (5.95 mL, 80.1 mmol), and
CH2Cl2 (18 mL) gave the crude product after acidic workup and further purified by flash
column chromatography (SiO2; 1:20 EtOAc/hexanes followed by 1:10 MeOH/CH2Cl2) to
give the desired compound (0.89 g, 76%) as a yellow oil: [α]28.5D +43.7° (c 1.0, CHCl3); Rf
0.50 (1:1 EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 0.72 (d, J = 6.8 Hz, 3H), 1.07 (d,
J = 6.8 Hz, 3H), 1.36 (s, 2H), 2.75–2.87 (m, 1H), 3.78 (d, J = 2.8 Hz, 1H), 4.84 (dd, J = 4.6,
15.0 Hz, 1H), 4.91 (dd, J = 5.0, 15.0 Hz, 1H), 7.29–7.38 (m, 5H), 9.75–9.95 (br s, 1H);
LRMS (ESI) 223.13 [M + H+] (calcd for C12H18N2SH+ 223.14); Anal. (C12H18N2S): C, H,
N.
(R)-1-N′-Benzylamino-2-amino-3-methylbutane ((R)-8).37
(R)-36 (3.38 g, 16.4 mmol) was dissolved in anhydrous THF (65 mL) and cooled to 0 °C.
BH3•THF (1 M, 49.19 mL, 49.19 mmol) was added dropwise and the mixture was heated to
reflux (18 h). The mixture was cooled to 0 °C and aqueous 0.5 M HCl (100 mL) was slowly
added. The THF was evaporated in vacuo and Et2O (100 mL) was added to the acidic
aqueous solution. The aqueous layer was separated and the organic layer was extracted with
aqueous 0.5 M HCl (3 × 50 mL). All of the aqueous layers were combined and washed with
Et2O (2 × 100 mL). The aqueous layer was basified to pH 10–12 using aqueous 4 M NaOH
and extracted with CH2Cl2 (3 × 100 mL). The CH2Cl2 layers were combined and were
successively washed with a 1:1 mixture of EtOH/H2O (2 × 100 mL) and saturated aqueous
brine (2 × 100 mL), dried (Na2SO4), evaporated in vacuo, and purified three times by flash
column chromatography (SiO2; 1:100 MeOH/CH2Cl2) to give the desired product (0.53 g,
17%) as a pale yellow oil: [α]28D −31.4° (c 0.51, CH2Cl2) (lit.37 [α]20D − 30.4° (c 0.55,
CH2Cl2)), [α]28D −31.4° (c 1.9, CHCl3) (lit.38 (S): [α]25.4D +33.4° (c 1.80, CHCl3)); Rf 0.53
(1:20 MeOH/CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 0.90 (d, J = 6.8 Hz, 6H), 1.58–1.69
(m, 1H), 2.42–2.48 (m, 4H), 2.64–2.69 (m, 1H), 2.74 (dd, J = 3.2, 12.0 Hz, 1H), 3.78 (1/2
ABq, J = 13.4 Hz, 1H), 3.84 (1/2 ABq, J = 13.4 Hz, 1H), 7.22–7.35 (m, 5H); HRMS (ESI)
193.1705 [M + H+] (calcd for C12H20N2H+ 193.1695); Anal. (C12H20N2•H2O): C, H, N.
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(R)-3139, 40 (3.04 g, 9.96 mmol) was dissolved in MeOH (50 mL) and aqueous concentrated
HCl (4.9 mL, 59 mmol) was added. The reaction was heated at reflux (1 h) and then cooled
to room temperature before evaporating the solvent in vacuo to give a crude oil. The crude
product was triturated with hexanes (3x) to give the desired product (0.60 g, 25%) as a white
solid: mp 123–124 °C; [α]28D − 59.7° (c 1.1, CHCl3); Rf 0.49 (1:20 MeOH/CH2Cl2); 1H
NMR (400 MHz, CDCl3) δ 0.97 (d, J = 7.0 Hz, 3H), 1.17 (d, J = 7.0 Hz, 3H), 2.34–2.44 (br
m, 1H), 2.56–2.98 (m, 4H), 4.18–4.26 (br d, 1H), 7.16–7.24 (m, 5H), 8.57 (br s, 3H); LRMS
(ESI) 206.13 [M – Cl−] (calcd for C13H20NO 206.13); Anal. (C13H20ClNO): C, H, Cl, N.
(R)-O-Benzyl 2-Amino-3-methylbutanoate ((R)-10).41
1 M HCl in Et2O (165 mL) was added to a Et2O solution (10 mL) of (R)-3225, 42 (2.02 g,
6.58 mmol) at 0 °C. The reaction was stirred at room temperature (18 h) to give a cloudy
white solution. The solution was filtered but no substantial filtrate was collected. The
solvent was evaporated in vacuo to give a crude oil that was then redissolved in CH2Cl2 (10
mL). The organic layer was extracted with aqueous 1 M HCl (3 × 10 mL). The aqueous
layers were combined and washed with CH2Cl2 (2 × 30 mL). The aqueous layer was
basified to pH 10–12 with aqueous 4 M NaOH and extracted with CH2Cl2 (3 × 50 mL). The
second set of organic layers were combined and washed with saturated aqueous brine (2 ×
150 mL), dried (Na2SO4), and evaporated in vacuo. The crude product was purified by flash
column chromatography (SiO2; 1:20 EtOAc/hexanes followed by 1:10 MeOH/CH2Cl2) to
give the desired product (0.99 g, 72%) as a pale yellow oil: [α]28.5D −10.2° (c 1.1, CHCl3);
Rf 0.39 (1:1 EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 0.88 (d, J = 7.0 Hz, 3H), 0.96
(d, J = 7.0 Hz, 3H), 1.44 (s, 2H), 1.99–2.10 (m, 1H), 3.34 (d, J = Hz, 1H), 5.14 (1/2 ABq, J
= 12.2 Hz, 1H), 5.18 (1/2 ABq, J = 12.2 Hz, 1H), 7.30–7.39 (m, 5H); LRMS (ESI) 208.15
[M + H+] (calcd for C12H17NO2H+ 208.15); Anal. (C12H17NO2): C, H, N.
(R)-N′-Phenyl 2-Amino-3-methylbutanamide ((R)-11).43
Utilizing Method A with (R)-4044 (1.75 g, 5.99 mmol), TFA (6.67 mL, 89.8 mmol), and
CH2Cl2 (20 mL) gave the crude product after acidic workup and was further purified by
flash column chromatography (SiO2; 1:10–1:1 EtOAc/hexanes followed by 1:10 MeOH/
CH2Cl2) to give the desired compound (0.94 g, 82%) as a pale orange oil: [α]25D +82.5° (c
1.6, CH2Cl2); Rf 0.34 (1:1 EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 0.87 (d, J = 7.2
Hz, 3H), 1.04 (d, J = 7.2 Hz, 3H), 1.46 (s, 2H), 2.40–2.48 (m, 1H), 3.37 (d, J = 3.6 Hz, 1H),
7.09 (t, J = 7.2 Hz, 1H), 7.32 (t, J = 8.2 Hz, 2H), 7.60 (d, J = 8.2 Hz, 2H), 9.46–9.56 (br s,
1H); HRMS (ESI) 193.1343 [M + H+] (calcd for C11H16N2OH+ 193.1341); Anal.
(C11H16N2O•0.01H2O): C, H, N.
(R)-N′-Phenethyl 2-Amino-3-methylbutanamide ((R)-12)
Utilizing Method A with (R)-41 (1.37 g, 4.28 mmol), TFA (4.77 mL, 64.2 mmol), and
CH2Cl2 (15 mL) gave the crude product after acidic workup and further purified by flash
column chromatography (SiO2; 1:10–1:1 EtOAc/hexanes followed by 1:10 MeOH/CH2Cl2)
to give the desired compound (873 mg, 93%) as a pale yellow solid: mp 36–37 °C; [α]25D
+32.9° (c 1.0, CH2Cl2); Rf 0.19 (1:20 MeOH/CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 0.77
(d, J = 7.2 Hz, 3H), 0.96 (d, J = 7.2 Hz, 3H), 1.20–1.26 (s, 2H), 2.22–2.33 (m, 1H), 2.77–
2.88 (m, 2H), 3.19 (d, J = 4.0 Hz, 1H), 3.46– 3.62 (m, 2H), 7.20–7.32 (m, 5H); HRMS (ESI)
221.1643 [M + H+] (calcd for C13H20N2OH+ 221.1654); Anal. (C13H20N2O): C, H, N.
(R)-N′-Phenylpropyl 2-Amino-3-methylbutanamide ((R)-13)
Utilizing Method A with (R)-42 (5.00 g, 15.0 mmol), TFA (16.7 mL, 225 mmol), and
CH2Cl2 (50 mL) gave the crude product after acidic workup and further purified by flash
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column chromatography (SiO2; 1:20 EtOAc/hexanes followed by 1:10 MeOH/CH2Cl2) to
give the desired compound (3.02 g, 86%) as a pale yellow oil: [α]28.5D +30.1° (c 1.2,
CHCl3); Rf 0.21 (1:1 EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 0.81 (d, J = 7.2 Hz,
3H), 0.98 (d, J = 7.2 Hz, 3H), 1.30 (s, 2H), 1.79–1.90 (m, 2H), 2.23–2.34 (m, 1H), 2.65 (t, J
= 8.4 Hz, 2H), 3.19 (d, J = 4.0 Hz, 1H), 3.22–3.37 (m, 2H), 7.16–7.20 (m, 3H), 7.26–7.35
(m, 3H); HRMS (ESI) 235.1818 [M + H+] (calcd for C14H22N2OH+ 235.1810); Anal.
(C14H22N2O•0.16H2O): C, H, N.
(R)-N′-Phenylbutyl 2-Amino-3-methylbutanamide ((R)-14)
Utilizing Method A with (R)-43 (3.18 g, 9.13 mmol), TFA (10.2 mL, 137 mmol), and
CH2Cl2 (30 mL) gave the crude product after basic workup that was further purified by flash
column chromatography (SiO2; 1:20 EtOAc/hexanes followed by 1:10 MeOH/CH2Cl2) to
give the desired compound (2.16 g, 96%) as a pale yellow oil: [α]28.5D +29.9° (c 1.0,
CHCl3); Rf 0.53 (1:20 MeOH/CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 0.81 (d, J = 6.8 Hz,
3H), 0.97 (d, J = 6.8 Hz, 3H), 1.51–1.59 (m, 4H), 1.62–1.70 (m, 2H), 2.22–2.34 (m, 1H),
2.63 (t, J = 8.0 Hz, 2H), 3.20 (d, J = 4.0 Hz, 1H), 3.22–3.44 (m, 2H), 7.15–7.19 (m, 3H),
7.25–7.36 (m, 3H); HRMS (ESI) 249.1954 [M + H+] (calcd for C15H24N2OH+ 249.1967);
Anal. (C15H24N2O•0.0.6CH2Cl2): C, H, N.
(R)-2′-N′-(Trifluoromethoxy)benzyl 2-Amino-3-methylbutanamide ((R)-15)
Utilizing Method A with (R)-44 (6.00 g, 15.4 mmol), TFA (17.1 mL, 231 mmol), and
CH2Cl2 (50 mL) gave the crude product after acidic workup that was further purified by
flash column chromatography (SiO2; 1:20 EtOAc/hexanes followed by 1:10 MeOH/
CH2Cl2) to give the desired compound (3.70 g, 83%) as a pale yellow solid: mp 54–55 °C;
[α]28.5D +28.0° (c 1.0, CHCl3); Rf 0.59 (1:20 MeOH/CH2Cl2); 1H NMR (400 MHz, CDCl3)
δ 0.81 (d, J = 6.8 Hz, 3H), 0.98 (d, J = 6.8 Hz, 3H), 1.34 (s, 2H), 2.28–2.39 (m, 1H), 3.27 (d,
J = 4.0 Hz, 1H), 4.48–4.57 (m, 2H), 7.22–7.33 (m, 3H), 7.41–7.43 (m, 1H), 7.71–7.79 (br t,
1H); LRMS (ESI) 291.12 [M + H+] (calcd for C13H17F3N2O2H+ 291.12); Anal.
(C13H17F3N2O2): C, H, F, N.
(R)-3′-N′-(Trifluoromethoxy)benzyl 2-Amino-3-methylbutanamide ((R)-16)
Utilizing Method A with (R)-45 (3.00 g, 7.69 mmol), TFA (8.57 mL, 115 mmol), and
CH2Cl2 (25 mL) gave the crude product after acidic workup that was further purified by
flash column chromatography (SiO2; 1:20 EtOAc/hexanes followed by 1:10 MeOH/
CH2Cl2) to give the desired compound (1.81 g, 81%) as a pale yellow oil: [α]28.5D +20.6° (c
1.3, CHCl3); Rf 0.47 (1:20 MeOH/CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 0.83 (d, J = 7.0
Hz, 3H), 1.00 (d, J = 7.0 Hz, 3H), 1.38 (s, 2H), 2.31–2.40 (m, 1H), 3.30 (d, J = 4.0 Hz, 1H),
4.43 (dd, J = 6.2, 15.0 Hz, 1H), 4.51 (dd, J = 6.6, 15.0 Hz, 1H), 7.10–7.13 (m, 2H), 7.21–
7.22 (m, 1H), 7.34 (t, J = 8.0 Hz, 1H), 7.78–7.86 (br t, 1H); LRMS (ESI) 291.11 [M + H+]
(calcd for C13H17F3N2O2H+ 291.11); Anal. (C13H17F3N2O4): C, H, F, N.
(R)-N′-Cyclohexylmethyl 2-Amino-3-methylbutanamide ((R)-18)
Utilizing Method A with (R)-46 (3.60 g, 11.5 mmol), TFA (12.8 mL, 173 mmol), and
CH2Cl2 (38 mL) gave the crude product after acidic workup that was further purified by
flash column chromatography (SiO2; 1:20 EtOAc/hexanes followed by 1:10 MeOH/
CH2Cl2) to give the desired compound (2.34 g, 96%) as a white solid: mp 85–86 °C; [α]25D
+38.1° (c 1.1, CHCl3); Rf 0.59 (1:20 MeOH/CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 0.82
(d, J = 7.0 Hz, 3H), 0.89–0.99 (m, 2H), 0.99 (d, J = 7.0 Hz, 3H), 1.10–1.28 (m, 3H), 1.36 (s,
2H), 1.41–1.52 (m, 1H), 1.65–1.74 (m, 5H), 2.26–2.37 (m, 1H), 3.03–3.18 (m, 2H), 3.23 (d,
J = 3.6 Hz, 1H), 7.30–7.40 (br t, 1H); LRMS (ESI) 213.18 [M + H+] (calcd for
C12H24N2OH+ 213.18); Anal. (C12H24N2O): C, H, N.
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Utilizing Method B with 47 (2.00 mL, 21.9 mmol), NMM (3.13 mL, 28.5 mmol), IBCF
(3.10 mL, 24.1 mmol), and benzylamine (2.51 mL, 23.0 mmol) gave the crude product that
was recrystallized from hot EtOAc/hexanes to give the desired compound (1.18 g, 30%) as a
white solid: mp 54–55 °C (lit.45 mp 36.9–38 °C); Rf 0.67 (1:20 MeOH/CH2Cl2); 1H NMR
(400 MHz, CDCl3) δ 0.96 (t, J = 7.6 Hz, 3H), 1.65–1.74 (m, 2H), 2.20 (t, J = 8.0 Hz, 2H),
4.45 (d, J = 5.6 Hz, 2H), 5.66–5.78 (br s, 1H), 7.26–7.35 (m, 5H); HRMS (ESI) 178.1238
[M + H+] (calcd for C11H15NOH+ 178.1232); Anal. (C11H15NO•0.06H2O): C, H, N.
(R,S)-N-Benzyl 2-Methylbutanamide ((R,S)-21).46
Utilizing Method B with (R,S)-48 (2.00 mL, 18.3 mmol), NMM (2.62 mL, 23.8 mmol),
IBCF (2.60 mL, 20.2 mmol), and benzylamine (2.10 mL, 19.3 mmol) gave the crude product
that was purified twice by flash column chromatography (SiO2; 1:20 EtOAc/hexanes) to
give the desired compound (2.32 g, 66%) as a white solid: mp 54–55 °C (lit.46 mp 47.5–48.5
°C); Rf 0.80 (1:1 EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 0.91 (t, J = 7.2 Hz, 3H),
1.15 (d, J = 6.2 Hz, 3H), 1.39–1.50 (m, 1H), 1.64–1.75 (m, 1H), 2.09– 2.17 (m, 1H), 4.39–
4.49 (m, 2H), 5.79–5.89 (br s, 1H), 7.26–7.35 (m, 5H); HRMS (ESI) 214.1199 [M + Na+]
(calcd for C12H17NOH+ 214.1208); Anal. (C12H17NO): C, H, N.
(S)-N-Benzyl 2-Methylbutanamide ((S)-21).47
Utilizing Method B with (S)-48 (0.90 mL, 8.27 mmol), NMM (1.18 mL, 10.8 mmol), IBCF
(1.17 mL, 9.10 mmol), and benzylamine (0.95 mL, 8.6 mmol) gave the crude product that
was purified twice by flash column chromatography (SiO2; 1:20 EtOAc/hexanes) to give the
desired compound (1.01 g, 64%) as a white solid: mp 55–56 °C; [α]28D +15.5° (c 1.0,
acetone) (lit.47 [α]D +16.96° (c 1.0, acetone)); Rf 0.80 (1:1 EtOAc/hexanes); 1H NMR (400
MHz, CDCl3) δ 0.91 (t, J = 7.6 Hz, 3H), 1.16 (d, J = 7.6 Hz, 3H), 1.40–1.50 (m, 1H), 1.65–
1.75 (m, 1H), 2.09–2.18 (m, 1H), 4.39–4.49 (m, 2H), 5.80–5.88 (br s, 1H), 7.25–7.35 (m,
5H); LRMS (ESI) 193.16 [M + H+] (calcd for C12H17NOH+ 193.16); Anal. (C12H17NO): C,
H, N.
(R)-N-Benzyl 2-Hydroxybutanamide ((R)-22)
To anhydrous toluene (80 mL) was added (R)- 49 (1.70 g, 16.3 mmol), benzylamine (1.78
mL, 16.3 mmol), and 3,5-bis(trifluoromethyl)benzene boronic acid (50) (0.42 g, 1.6 mmol).
A pressure equalizing dropping funnel containing a cotton plug was filled 1/3 of the way
with 3 Å molecular sieves that were oven dried (120 °C) and a condenser was placed above
the dropping funnel. The mixture was heated at reflux (18 h) before cooling to room
temperature and then the solvent was evaporated in vacuo. The crude product was purified
by flash column chromatography (SiO2; 1:20–1:1 EtOAc/hexanes followed by 1:10 MeOH/
CH2Cl2) followed by recrystallization from hot EtOAc/hexanes to give the desired
compound (1.05 g, 33%) as a white solid: mp 63–64 °C; [α]28.5D +28.3° (c 2.2, CHCl3); Rf
0.56 (1:20 MeOH/CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 0.96 (t, J = 7.6 Hz, 3H), 1.63–
1.74 (m, 1H), 1.82–1.92 (m, 1H), 3.32 (d, J = 4.8 Hz, 1H), 4.07–4.11 (m, 1H), 4.38–4.48 (m,
2H), 6.95– 7.20 (br t, 1H), 7.24–7.34 (m, 5H); LRMS (ESI) 216.12 [M + Na+] (calcd for
C11H15NO2Na+ 216.12); Anal. (C11H15NO2): C, H, N.
(R)-N′-Benzyl N-(Methyl)amino-2-methylbutanamide Hydrochloride ((R)-23)
HCl in dioxane (4 mL, 4 M) was added at 0 °C to an Et2O (1 mL) solution of (R)-53 (620
mg, 4.7 mmol). The reaction was stirred at room temperature (16 h) and then concentrated in
vacuo. The residue was triturated with Et2O to give the desired compound (450 mg, 90%) as
a white solid: mp 120–125 °C; [α]27D +93.8°(c 0.5, CH3OH); 1H NMR (400 MHz, CD3OD)
δ 1.02 (d, J = 7.2 Hz, 3H), 1.05 (d, J = 6.9 Hz, 3H), 2.18–2.24 (m, 1H), 2.65 (s, 3H), 3.62 (d,
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J = 5.1 Hz, 1H), 4.40 (1/2 ABq, J = 15.0 Hz, 1H), 4.50 (1/2 ABq, J = 15.0 Hz, 1H), 7.28–
7.34 (m, 5H); HRMS (ESI) 221.1654 [M+H+] (calcd. for C13H20N2OH+ 221.1653); Anal.
(C13H20N2O): C, H, Cl, N.
(R)-N′-Benzyl N,N-Dimethylamino-3-methylbutanamide ((R)-24)
(R)-55 (2.28 g, 15.7 mmol) and benzylamine (2.06 mL, 18.9 mmol) were added to
anhydrous THF (160 mL) at room temperature. The mixture stirred (15 min) and then
DMTMM (5.22 g, 18.9 mmol) was added in one portion. The reaction continued at room
temperature overnight (18 h) and then the insoluble salts were filtered, evaporated in vacuo,
and purified by flash column chromatography (SiO2; 2:1 EtOAc/CH2Cl2 followed by 1:10
MeOH/CH2Cl2) to give the desired product (0.38 g, 10%) as a white solid: mp 78–79 °C;
[α]28D −11.2° (c 0.5, CHCl3); Rf 0.55 (1:20 MeOH/CH2Cl2); 1H NMR (400 MHz, CDCl3) δ
0.89 (d, J = 6.6 Hz, 3H), 1.03 (d, J = 6.6 Hz, 3H), 2.04–2.17 (m, 1H), 2.25 (s, 6H), 2.48 (d, J
= 6.0 Hz, 1H), 4.42–4.51 (m, 2H), 6.58–6.65 (br t, 1H), 7.25–7.35 (m, 5H); LRMS (ESI)
235.17 [M + H+] (calcd for C14H22N2OH+ 235.17); Anal. (C14H22N2O): C, H, N.
(R)-2′-N′-(Fluoro)phenethyl 2-Amino-3-methylbutanamide ((R)-56)
Utilizing Method A with (R)-2′-N′-(fluoro)phenethyl 2-N-(t-butoxycarbonyl)amino-3-
methylbutanamide (9.00 g, 26.6 mmol), TFA (30 mL, 0.40 mol), and CH2Cl2 (90 mL) gave
the crude product after acidic workup and further purified by flash column chromatography
(SiO2; 1:20 EtOAc/hexanes followed by 1:10 MeOH/CH2Cl2) to give the desired compound
(5.76 g, 91%) as a white solid: mp 51–52 °C; [α]28D +32.6° (c 1.5, CHCl3); Rf 0.26 (1:20
MeOH/CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 0.77 (d, J = 7.0 Hz, 3H), 0.95 (d, J = 7.0
Hz, 3H), 1.25 (s, 2H), 2.24–2.32 (m, 1H), 2.82–2.93 (m, 2H), 3.19 (d, J = 3.6 Hz, 1H), 3.46–
3.61 (m, 2H), 6.99–7.09 (m, 2H), 7.17–7.23 (m, 2H), 7.34–7.42 (br t, 1H); LRMS (ESI)
239.13 [M + H+] (calcd for C13H19FN2OH+ 239.13); Anal. (C13H19FN2O): C, H, F, N.
(R)-3′-N′-(Fluoro)phenethyl 2-Amino-3-methylbutanamide ((R)-57)
Utilizing Method A with (R)-3′-N-(fluoro)phenethyl 2-N-(t-butoxycarbonyl)amino-3-
methylbutanamide (8.50 g, 25.1 mmol), TFA (28 mL, 0.38 mol), and CH2Cl2 (85 mL) gave
the crude product after acidic workup and further purified by flash column chromatography
(SiO2; 1:20 EtOAc/hexanes followed by 1:10 MeOH/CH2Cl2) to give the desired compound
(5.08 g, 85%) as a pale yellow oil: [α]28D +31.4° (c 1.1, CHCl3); Rf 0.26 (1:20 MeOH/
CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 0.77 (d, J = 7.0 Hz, 3H), 0.96 (d, J = 7.0 Hz, 3H),
1.23 (s, 2H), 2.23–2.34 (m, 1H), 2.77–2.88 (m, 2H), 3.20 (d, J = 4.0 Hz, 1H), 3.45–3.61 (m,
2H), 6.89–6.93 (m, 2H), 6.97–6.99 (m, 1H), 7.23–7.28 (m, 1H), 7.34–7.44 (br t, 1H); HRMS
(ESI) 239.1553 [M + H+] (calcd for C13H19FN2OH+ 239.1560); Anal.
(C13H19FN2O•0.01H2O): C, H, F, N.
(R)-4′-N′-(Fluoro)phenethyl 2-Amino-3-methylbutanamide ((R)-58)
Utilizing Method A with (R)-4′-N′-(fluoro)phenethyl 2-N-(t-butoxycarbonyl)amino-3-
methylbutanamide (9.00 g, 26.6 mmol), TFA (30 mL, 0.40 mol), and CH2Cl2 (90 mL) gave
the crude product after acidic workup and further purified by flash column chromatography
(SiO2; 1:20 EtOAc/hexanes followed by 1:10 MeOH/CH2Cl2) to give the desired compound
(5.82 g, 92%) as a pale yellow oil: [α]28D +31.8° (c 1.5, CHCl3); Rf 0.19 (1:20 MeOH/
CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 0.77 (d, J = 7.0 Hz, 3H), 0.96 (d, J = 7.0 Hz, 3H),
1.23 (s, 2H), 2.22–2.33 (m, 1H), 2.74–2.85 (m, 2H), 3.19 (d, J = 3.6 Hz, 1H), 3.42–3.59 (m,
2H), 6.95–7.00 (m, 2H), 7.13–7.18 (m, 2H), 7.34– 7.42 (br t, 1H); LRMS (ESI) 239.13 [M +
H+] (calcd for C13H19FN2OH+ 239.13); Anal. (C13H19FN2O): C, H, F, N.
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Compounds were screened under the auspices of UCB Pharma (Braine L’Alleud, Belgium)
and the NINDS ASP (Rockville, MD). Housing, handling, and feeding were in full
accordance with recommendations contained in the “Guide for the Care and Use of
Laboratory Animals.”48 Pharmacological evaluation by UCB Pharma consisted of the MES
test33 to assess anticonvulsant activity and the rotorod test33 to assess neurological toxicity.
Pharmacological evaluation by the NINDS ASP utilized male albino Carworth Farms No. 1
mice (ip) or male albino Sprague-Dawley rats (po) and consisted of the MES test (mice and
rats) and the subcutaneous pentylenetetrazol (Metrazol®) (scMet) seizure threshold test5 to
assess anticonvulsant activity (mice), the rotorod test to assess neurological toxicity (mice),
and the positional sense test or gait and stance test to assess behavioral toxicity (rats).5
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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C(2)-Isopropyl PAAD (R)-3 Analogs (Sites A-F)
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Synthesis of (R)-N′-benzyl 2-amino-3-methylthiobutanamide ((R)-7)
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Synthesis of (R)-1-N-benzylamino-2-amino-3-methylbutane ((R)-8)
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Synthesis of (R)-4-amino-2-methyl-6-phenyl-4-hexanone hydrochloride ((R)- 9)
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Synthesis of (R)-O-benzyl 2-amino-3-methylbutanoate ((R)-10)
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Synthesis of C(2)-isopropyl PAADs (R)-11–16 and (R)-18
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Synthesis of C(2)-isopropyl analogs: α-Substituted N-benzylbutanamides 20, (R,S)-21,
(S)-21, and (R)-22
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Synthesis of (R)-N′-benzyl N,N-dimethylamino-3-methylbutanamide ((R)-23)
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Synthesis of (R)-N′-benzyl N,N-dimethylamino-3-methylbutanamide ((R)-24)
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